Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:ABT-737
go back to main search page
Accession:CHEBI:47575 term browser browse the term
Definition:A biphenyl that is 4-chloro-1,1'-biphenyl substituted by a (4-{4-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)carbamoyl]phenyl}piperazin-1-yl)methyl group at position 2'. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells.
Synonyms:exact_synonym: 4-{4-[(4'-chloro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]benzamide
 related_synonym: 4-{4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]piperazin-1-yl}-N-(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)benzamide;   ABT737;   Formula=C42H45ClN6O5S2;   InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1;   InChIKey=HPLNQCPCUACXLM-PGUFJCEWSA-N;   SMILES=CN(C)CC[C@H](CSC1=CC=CC=C1)NC1=C(C=C(C=C1)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC2=CC=CC=C2C2=CC=C(Cl)C=C2)CC1)[N+]([O-])=O
 xref: CAS:852808-04-9;   Chemspider:9403232;   LINCS:LSM-1180
 xref_mesh: MESH:C501332
 xref: PDBeChem:N3C;   PMID:17572662;   PMID:26880588;   PMID:29543705;   PMID:29792865;   PMID:29856968;   PMID:30389373;   PMID:30402442;   PMID:30557204;   PMID:30625226;   PMID:30721730;   PMID:31493778;   PMID:31579427;   PMID:31612056;   PMID:31906234;   PMID:32079453;   PMID:32083466;   PMID:32139422;   PMID:32212793;   PMID:32424251;   PMID:32470451;   PMID:32580291;   PMID:32623836;   PMID:32811502;   PMID:32966375;   PMID:33140666;   PMID:33218059;   PMID:33396645;   PMID:33523649;   PMID:33786632;   PMID:33787344;   Wikipedia:ABT-737


show annotations for term's descendants           Sort by:
ABT-737 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]] CTD PMID:32802178 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bag3 BAG cochaperone 3 decreases response to substance
multiple interactions		 ISO BAG3 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]		 CTD PMID:23341456 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects folding
multiple interactions		 ISO ABT-737 affects the folding of BAX protein
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [ABT-737 co-treated with hydroquinone] results in increased expression of BAX protein; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]		 CTD PMID:17097560 PMID:17200714 PMID:21880625 PMID:28843007 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance		 ISO ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Vorinostat]
BCL2 protein modified form results in decreased susceptibility to ABT-737
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased phosphorylation of BCL2 protein] which results in increased susceptibility to ABT-737; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [ABT-737 results in decreased activity of BCL2 protein] which results in increased susceptibility to fosbretabulin; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]		 CTD PMID:17097560 PMID:17200714 PMID:19060243 PMID:20104024 PMID:24321340 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
increases expression		 ISO ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Vorinostat]
ABT-737 results in increased expression of BCL2L1 protein alternative form
ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]		 CTD PMID:18628207 PMID:19060243 PMID:21256112 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases response to substance		 ISO [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]
BCL2L11 protein results in increased susceptibility to ABT-737		 CTD PMID:17097560 PMID:17200714 PMID:20038611 PMID:23341456 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Becn1 beclin 1 multiple interactions ISO ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]] CTD PMID:18628207 PMID:32061152 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [ABT-737 co-treated with Celecoxib] results in increased cleavage of BID protein CTD PMID:20104024 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463 		JBrowse link
G Casp3 caspase 3 increases cleavage
increases activity
multiple interactions		 ISO ABT-737 results in increased cleavage of CASP3 protein
ABT-737 results in increased activity of CASP3 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP3 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP3 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]		 CTD PMID:19010845 PMID:19773376 PMID:20038611 PMID:20104024 PMID:23353698 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 increases activity ISO ABT-737 results in increased activity of CASP7 protein CTD PMID:20038611 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp8 caspase 8 increases cleavage
multiple interactions		 ISO ABT-737 results in increased cleavage of CASP8 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP8 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]		 CTD PMID:20104024 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions
increases cleavage		 ISO ABT-737 results in increased activity of CASP9 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP9 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP9 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]		 CTD PMID:20104024 PMID:23353698 PMID:30461186 PMID:33662508 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO [ABT-737 co-treated with hydroquinone] results in increased expression of H2AX protein CTD PMID:28843007 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Krt18 keratin 18 increases cleavage ISO ABT-737 results in increased cleavage of KRT18 protein CTD PMID:19010845 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases response to substance
multiple interactions		 ISO MCL1 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; [Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]		 CTD PMID:17097560 PMID:17688235 PMID:21880625 PMID:23341456 PMID:32802178 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions
decreases expression		 ISO [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
ABT-737 results in decreased expression of MKI67 protein		 CTD PMID:19773376 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Nanog Nanog homeobox decreases expression ISO ABT-737 results in decreased expression of NANOG protein CTD PMID:23918355 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein; [ABT-737 co-treated with hydroquinone] results in increased cleavage of PARP1 protein; ABT-737 inhibits the reaction [hydroquinone affects the localization of PARP1 protein]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:28843007 PMID:32802178 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases response to substance ISO PMAIP1 protein results in increased susceptibility to ABT-737 CTD PMID:17688235 NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429 		JBrowse link
G Rassf1 Ras association domain family member 1 multiple interactions ISO ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Cisplatin]; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] CTD PMID:21880625 NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Celecoxib co-treated with ABT-737] results in decreased expression of SQSTM1 protein; ABT-737 promotes the reaction [Silicon Dioxide results in decreased expression of SQSTM1 protein] CTD PMID:20104024 PMID:32061152 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [ABT-737 co-treated with hydroquinone] results in increased expression of TRP53 protein CTD PMID:28843007 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Usp7 ubiquitin specific peptidase 7 multiple interactions ISO USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:32802178 NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19922
    role 19894
      application 19735
        anti-inflammatory agent 16628
          ABT-737 28
Path 2
Term Annotations click to browse term
  CHEBI ontology 19922
    subatomic particle 19892
      composite particle 19892
        hadron 19920
          baryon 19892
            nucleon 19920
              atomic nucleus 19892
                atom 19892
                  main group element atom 19866
                    main group molecular entity 19838
                      s-block molecular entity 19698
                        hydrogen molecular entity 19679
                          hydrides 19181
                            inorganic hydride 18192
                              pnictogen hydride 18157
                                nitrogen hydride 18070
                                  azane 17873
                                    ammonia 17898
                                      organic amino compound 17898
                                        tertiary amino compound 10158
                                          N-arylpiperazine 3441
                                            ABT-737 28
paths to the root